Compounded Semaglutide Explained: What Adults Should Know

A responsible read on healthRX starts with mechanism, side effects, access, and monitoring rather than promises. That frame keeps the discussion useful for patients without pretending the evidence is stronger than it is.

Last fall, a patient I’ll call Sarah sat in my office with her phone open to three browser tabs: one for Wegovy’s manufacturer coupon page, one for her insurer’s formulary, and one for a telehealth compounding program she’d found on TikTok. Her BMI was 34. Her A1c was creeping toward prediabetes range. Her insurance plan covered Wegovy only with a prior authorization that her HR department warned “never goes through.” She looked at me and asked the question I now hear weekly: “Is the compounded version the same thing, or am I getting scammed?”

The honest answer is more complicated than either “yes, same thing” or “no, stay away.” And that complexity is exactly what this piece is about.

The Active Ingredient vs. the Finished Product

Semaglutide is a GLP-1 receptor agonist. Novo Nordisk developed it and brought it to market as Ozempic (2017, for type 2 diabetes) and Wegovy (2021, for chronic weight management). Both are FDA-approved finished products manufactured at industrial scale.

Compounded semaglutide uses the same active pharmaceutical ingredient. A state-licensed or 503A compounding pharmacy prepares it for an individual patient under a clinician’s prescription. That is a legal, regulated pathway under section 503A of the Federal Food, Drug, and Cosmetic Act. But the finished preparation itself is not FDA-approved.

This is not a semantic distinction. It means the STEP and SUSTAIN trials, the ones that generated all those “15% body weight loss” headlines, were conducted using brand-name semaglutide. The pharmacology of the molecule doesn’t change when a different pharmacy prepares it. But the manufacturing process, the quality oversight model, and the adverse-event surveillance infrastructure are all different. A careful patient should know this. An honest provider should say it.

What the Trial Data Actually Shows

The clinical case for semaglutide as a weight-management drug rests on a substantial evidence base.

STEP-1 randomized 1,961 adults with overweight or obesity (without diabetes) to weekly semaglutide 2.4 mg or placebo for 68 weeks, with a lifestyle intervention layered in. The semaglutide group lost approximately 14.9% of body weight versus 2.4% in the placebo arm (Wilding et al., New England Journal of Medicine, 2021). That’s a real effect. It’s also a mean. Individual responders in STEP-1 ranged widely, from modest single-digit losses to well over 20%.

STEP-3 added intensive behavioral therapy and saw a directionally similar, somewhat larger effect. STEP-5 followed patients for 104 weeks and showed sustained weight reduction in the active arm. STEP-4 is the one that gets less press but matters a lot: patients who were switched to placebo after an initial treatment period showed significant weight regain, suggesting the metabolic effect depends on staying on therapy for many people.

On the diabetes side, the SUSTAIN program (including SUSTAIN-6, Marso et al.) established the glycemic benefit at lower doses (0.5 mg, 1.0 mg, and later 2.0 mg weekly via SUSTAIN FORTE) and showed a reduction in major adverse cardiovascular events in high-risk diabetes patients.

The boring truth about these trials: they tell us semaglutide works. They do not tell us whether a specific compounding pharmacy’s preparation works identically. The pharmacology strongly suggests it should, but “strongly suggests” and “was proven in a Phase 3 trial” are different evidentiary categories, and patients deserve to know which one they’re operating in.

Titration, Dosing, and the Details That Actually Affect Your Experience

The standard titration schedule from the STEP trials (and the Wegovy label) looks like this: 0.25 mg weekly for four weeks, then 0.5 mg for four, then 1.0 mg for four, then 1.7 mg for four, then 2.4 mg as the maintenance dose. Full escalation takes about 16 to 17 weeks if you move through every step on schedule.

Most compounded programs follow the same milligram increments. Where they differ is concentration of the solution and, therefore, the volume you draw into the syringe. This trips people up more than it should. The dose is the milligram number, not the amount of liquid. If you’re switching programs or pharmacies, confirm the milligrams at every step.

The schedule is also not a forced march. A patient struggling with nausea at 0.5 mg can stay there for an extra four weeks. A patient doing well clinically at 1.7 mg can park there and skip the jump to 2.4 mg entirely. That’s a clinical decision, not an administrative one, and a good program treats it that way.

On the practical side: refrigerate at 36 to 46°F. Rotate injection sites between abdomen, thigh, and upper arm. These details sound minor until you’re the person with a red, irritated spot in the same place three weeks running because nobody mentioned rotation.

Side Effects: What’s Common, What’s Rare, What’s Serious

The GI side effects are the headliner. Nausea, diarrhea, constipation, vomiting, abdominal discomfort. These were reported across STEP and SUSTAIN and they show up reliably in real-world cohorts too. Most are mild to moderate, concentrated in the first 8 to 12 weeks, and resolve with continued therapy or a temporary dose adjustment. They’re unpleasant. They’re also manageable.

Less common but clinically important: gallbladder events (especially with rapid weight loss), acute pancreatitis (rare, but persistent severe abdominal pain radiating to the back needs urgent evaluation), and a theoretical thyroid C-cell tumor signal from rodent data that has not been replicated in humans. The Wegovy and Ozempic labels carry a boxed warning about the rodent finding and contraindicate the drug in patients with personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2 (MEN2).

Hypoglycemia is uncommon on semaglutide alone in non-diabetic patients because the drug’s insulin-stimulating effect is glucose-dependent. The risk jumps when you combine it with insulin or sulfonylureas, and in that scenario, dose adjustment of the other agent is the key safety move.

My honest take: the safety profile of semaglutide is well-characterized and, for most patients, manageable. The real danger isn’t the drug. It’s a program that doesn’t run a proper intake conversation, doesn’t ask about your medication list, and doesn’t have a protocol for when you call with worrisome symptoms at week six.

The Cost Question (Because That’s Why Most People Are Here)

Let’s not pretend otherwise. The primary reason compounded semaglutide has a market is the price gap.

Brand-name Wegovy and Ozempic carry list prices north of $1,300 per month. Cash-pay at most retail pharmacies runs $1,000 to $1,400. Insurance coverage for the weight-management indication is inconsistent at best. The diabetes indication fares somewhat better, but “somewhat better” still means prior authorizations, step therapy requirements, and coverage denials that vary by plan, by employer, and sometimes by the mood of the utilization reviewer.

Compounded programs running through compliant telehealth structures price substantially lower. HealthRX, as one example, publishes rates of $179.99 to $279.99 per month depending on dose, operates in 44 U.S. states, and holds LegitScript certification.

The pricing gap is structural, not suspicious. Brand-name products carry the cost of Phase 3 trials, FDA submissions, post-marketing surveillance, and commercial margins that fund the next pipeline molecule. Compounded preparations are produced at a different scale, through a different regulatory pathway, with a fundamentally different cost structure. Think of it like the difference between a branded drug and a generic after patent expiration, except the regulatory analogy isn’t perfect because compounded preparations don’t go through an ANDA process.

If you’re using an HSA or FSA, confirm the program’s invoicing format before you enroll. Some plans accept compounded medication receipts without issue. Others want specific documentation.

When to Call Your Clinician (Not Google)

Certain scenarios need a phone call, not a Reddit search:

Persistent severe abdominal pain, especially with radiation to the back or fever. Inability to keep fluids down for more than 24 hours, signs of dehydration, or persistent vomiting. New right upper quadrant pain after meals, or jaundice. New or worsening reflux that doesn’t respond to meal-timing changes. Mood changes, including new depressive symptoms. Any of these deserve prompt contact with your prescribing program or treating clinician.

Pregnancy, planned pregnancy, or breastfeeding: talk to your provider before the next dose. Personal or family history of medullary thyroid carcinoma or MEN2 should have been caught at intake. If it wasn’t, that’s a conversation to have immediately.

Patients on insulin, sulfonylureas, or other glucose-lowering agents who notice hypoglycemic episodes need dose adjustment of the concurrent therapy. Patients on warfarin or other narrow-therapeutic-window medications should discuss whether semaglutide’s gastric-emptying effect could alter absorption of those drugs.

Frequently Asked Questions

Is compounded semaglutide the same drug as Ozempic and Wegovy?

The active ingredient, semaglutide, is the same. The regulatory category, finished product, and manufacturing pathway are different. Brand-name Ozempic and Wegovy are FDA-approved finished products manufactured by Novo Nordisk. Compounded semaglutide is prepared by a licensed compounding pharmacy for an individual patient under a clinician’s prescription and is not FDA-approved as a finished product.

How long does treatment typically last?

STEP-1 captures 68 weeks of treatment; STEP-5 extends to 104 weeks. Clinical experience now reaches beyond two years. Duration is individualized based on the patient’s goals, response, and tolerability.

Is the weight loss sustained after stopping?

The STEP-4 data says: for many patients, no. Significant regain occurred in the group switched to placebo after a lead-in treatment period. Long-term maintenance after discontinuation depends on the lifestyle changes a patient has consolidated during treatment.

Do I need labs to start?

A well-run program will document baseline labs, typically a metabolic panel, lipid panel, A1c, and in some patients, a thyroid panel. Specifics depend on the clinical picture.

Is semaglutide right for everyone?

No. Pregnancy, breastfeeding, personal or family history of medullary thyroid carcinoma or MEN2, and certain GI conditions are contraindications or relative contraindications. A real intake conversation surfaces these before therapy begins.

How do compounded and brand-name semaglutide differ in terms of oversight?

Brand-name products are manufactured under FDA current Good Manufacturing Practice (cGMP) requirements. Compounded preparations are regulated by state boards of pharmacy and, for 503B outsourcing facilities, by the FDA under a separate framework. The adverse-event reporting infrastructure is also less comprehensive for compounded preparations.

Can I switch from compounded to brand-name (or vice versa)?

Yes, with clinician guidance. The key is confirming the milligram dose at each step. The volume of injection may differ, but the clinical dose should remain consistent across transitions.

References: Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine 2021;384:989-1002 (STEP-1). Wadden TA et al. STEP-3. Rubino DM et al. STEP-4. Garvey WT et al. STEP-5. Davies M et al. STEP-2. SUSTAIN-6 (Marso SP et al.). Wegovy and Ozempic prescribing information (Novo Nordisk).

Important Notice

Not FDA-approved. Compounded semaglutide is prepared by licensed compounding pharmacies for individual patients based on a prescriber’s clinical judgment. This article is educational and does not constitute medical advice. Individual results vary.